Core Viewpoint - The company has launched a new equity incentive plan aimed at enhancing its market-oriented and long-term incentive mechanisms, driving performance growth, and strengthening its core team's talent advantage [1][2]. Group 1: Equity Incentive Plan Details - The first batch of the equity incentive plan is closely tied to the company's performance growth targets for the next three years, requiring revenue growth of at least 35%, 75%, and 125% by the end of 2025, 2026, and 2027, respectively, compared to 2024 [2]. - The company’s revenue for 2024 is projected to be 780 million yuan, with the incentive plan suggesting potential revenue nearing 1.8 billion yuan within three years, positioning the company among the top tier in the domestic medical device industry [2]. Group 2: Market Context and Competitive Position - The domestic high-value consumables market is undergoing significant changes due to deepening centralized procurement policies, and the company has emerged as the first successful Hong Kong-listed medical device company to transition from 18A to B status, highlighting its growth potential [2]. - The introduction of the equity incentive plan is seen as a crucial internal mechanism to drive the company's rapid growth and strategic breakthroughs [2]. Group 3: Incentive Structure and Market Pricing - The equity incentive plan will utilize restricted stock units (RSUs) with a purchase price of 20 HKD per share, which is below the latest closing price of 25.46 HKD, reflecting a market-oriented approach that is relatively rare in the Hong Kong market [3]. - Typically, Hong Kong-listed companies grant RSUs for free, while the company’s approach aligns employee interests with shareholder interests, demonstrating confidence in future growth [3]. Group 4: Leadership Perspective - The CEO emphasized that the long-term value of the company is derived from continuous creation and collective effort, and the incentive plan reflects the commitment to future growth and value creation for shareholders and employees [4].